Press Releases

Press Releases

  • Oct 9, 2017
    NLS wins prestigious Innovation Award in Paris. Over 300 candidates participated in the race.

    READ MORE

  • May 31, 2017
    NLS Pharma unveils positive phase 2 data for NLS-1 (Mazindol CR) in adults with ADHD, demonstrating significant improvement in symptoms

    READ PRESS RELEASE

  • May 26, 2017
    NLS Pharma announces new information in support of the mechanism of action of its lead compound NLS-1 Mazindol CR

    READ PRESS RELEASE

  • May 16, 2017
    NLS Pharma announces phase 2 study of NLS-1 (MAZINDOL) in adult ADHD patients has met all primary and secondary endpoints

    READ PRESS RELEASE

  • April 20, 2017
    NLS Pharma Announces Presentations at 6th World Congress on ADHD

    READ PRESS RELEASE

  • April 18, 2017
    NLS Pharma Announces Completion of Phase 2 Study for NLS-1, Its Lead ADHD Compound; New Investors, New Patents

    READ PRESS RELEASE

  • December 3, 2016
    NLS Pharma Named Winner Of A Prestigous 2016 Healthcare & Life Sciences Award

    READ PRESS RELEASE

  • August 29, 2016
    NLS Pharma announces start of its phase 2 trial for Mazindol in adult ADHD patients

    READ PRESS RELEASE

  • July 11, 2016
    Mazindol granted orphan drug designation in the US & Europe for treatment of Narcolepsy

    READ PRESS RELEASE

  • June 16, 2016
    FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD

    READ PRESS RELEASE

  • May 12, 2016
    NLS Pharma Announces IND submission for Controlled-Release Mazindol to Treat Adults with ADHD.

    READ PRESS RELEASE